Translational Challenge
Chronic Respiratory Infection
Our vision is to enable people with bronchiectasis and cystic fibrosis to live longer, with an improved quality of life by breaking the cycle of infection, inflammation and lung damage.
We progress discoveries that can intervene earlier, reduce treatment burden and improve the quality of life for those living with cystic fibrosis and bronchiectasis.
People living with these conditions are caught in a vicious cycle of infection, inflammation and permanent lung damage – and running low on treatment options due to antibiotic resistance or a lack of effective therapies.
While chronic lung infection is common in people living with these conditions, acute flare ups cause deterioration of lung health, resulting in frequent hospitalisations for emergency treatment.
Better ways are needed to treat and manage these conditions through improved therapeutics and diagnostics.
300,000+
adults in the UK have bronchiectasis
Over 11,000
people in the UK are living with cystic fibrosis
What do we want to achieve?
We’re focused on early detection, right diagnosis and better treatments, by enabling:
- tools to predict exacerbations much earlier, and help people living with these conditions receive the right treatment sooner
- new diagnostics to improve clinical decision making
- access to new treatments, including repurposed drugs, that tackle infection, inflammation and reduce side effects and the burden of treatment
- people living with these conditions to live longer, with less severe chronic and recurrent infections, reduced exacerbations and a better quality of life
How you can work with us
We collaborate with academics, charities, healthcare professionals and industry on projects to find:
New digital tools and data approaches to predict exacerbations earlier
New diagnostics tools and approaches to improve clinical decision making
New therapies, including repurposed drugs
Commercial, legal and regulatory process to protect your intellectual property
Partnerships and initiatives
Drug repurposing call to treat chronic respiratory infection
LifeArc has committed £10m to fund up to five consortia programmes that seek to develop therapeutics that can provide a clear rationale for the use in these conditions.
£3 million to accelerate development of new cystic fibrosis therapies
LifeArc, as part of the CF AMR Syndicate, is providing £3 million in collaborative funding to drug discovery innovators to accelerate the development of new treatments for people with cystic fibrosis.
See our resources on translating science related to chronic respiratory infections.
Who to contact
-
Katy Kettleborough
Read bio: Katy Kettleborough
See our other Translational Challenges
Motor Neuron Disease
Our vision is a world where motor neuron disease is preventable and treatable.
Global Health
Our vision is a world with affordable and accessible solutions to better understand, treat, and prevent infectious diseases.
Rare Disease
Our vision is an ecosystem working together to get discoveries and treatments to rare disease patients faster.
Childhood Cancer
Our vision is to drive life-changing innovations for children with cancer.
Contact us
In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. If you would like your data to be removed, please email info@lifearc.org.
Please see our Privacy Policy in relation to the personal data you submit to us through this page.